InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

- Current share price for MSB : $1.990

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,590 First Minimally Invasive Procedure for Lumbar Disc Repair 22 Aug 2011 8:32AM $7.170 $1.990 fallen by 72.25%
$2,590 Appendix 4C - quarterly 1 Aug 2011 8:18AM $9.270 $1.990 fallen by 78.53%
$2,590 FDA Clearance for Phase 3 Bone Marrow Transplant Trial 7 Jul 2011 9:23AM $8.580 $1.990 fallen by 76.81%
$2,590 FDA Clears Phase 2 Trial to Treat Degenerative Disc Disease 29 Jun 2011 9:22AM $8.260 $1.990 fallen by 75.91%
$2,590 Key Product Franchises Featured at Nomura Asia Equity Forum 14 Jun 2011 12:26PM $8.530 $1.990 fallen by 76.67%
$2,590 Revascor Increases Blood Supply to Damaged Heart Muscle 9 Jun 2011 9:39AM $8.590 $1.990 fallen by 76.83%
$2,590 Key USA Patents Increase Commercial Rights and Indications 24 May 2011 9:40AM $8.500 $1.990 fallen by 76.59%
$2,590 Appendix 4C - quarterly 2 May 2011 8:18AM $8.150 $1.990 fallen by 75.58%
$2,590 Mesoblast Included in S and P/ASX 200 Index 18 Apr 2011 9:41AM $8.050 $1.990 fallen by 75.28%
$2,590 Mesoblast Update on Valeant Proposal to Cephalon 7 Apr 2011 9:19AM $7.770 $1.990 fallen by 74.39%
$2,590 Appendix 4D and Half Year Financial Report to 31 Dec 2010 28 Feb 2011 4:17PM $8.630 $1.990 fallen by 76.94%
$2,590 Appendix 4C - Strong Cash Position 31 Jan 2011 7:26PM $5.580 $1.990 fallen by 64.34%
$2,590 Response to ASX Price Query 13 Jan 2011 10:29AM $5.650 $1.990 fallen by 64.78%
$2,590 Cardiac Events, Mortality and Hospitalization Reduced 10 Jan 2011 6:41PM $4.620 $1.990 fallen by 56.93%
$2,590 Mesoblast Completes Acquisition of Angioblast 23 Dec 2010 10:11AM $4.570 $1.990 fallen by 56.46%
$2,590 Mesoblast And Cephalon Enter Into Strategic Alliance 8 Dec 2010 9:22AM $4.050 $1.990 fallen by 50.86%
$2,590 Trading Halt 6 Dec 2010 9:49AM $3.330 $1.990 fallen by 40.24%
$2,590 Mesoblast Clear To Proceed With Angioblast Acquisition 19 Nov 2010 2:17PM $2.950 $1.990 fallen by 32.54%
$2,590 Novel Heart Attack Treatment Results Presented to US Forum 16 Nov 2010 9:47AM $2.990 $1.990 fallen by 33.44%
$2,590 US Govt Grants for Further Development of Stem Cell Products 8 Nov 2010 9:41AM $2.700 $1.990 fallen by 26.30%
$2,590 Appendix 4C - quarterly 29 Oct 2010 11:12AM $2.990 $1.990 fallen by 33.44%
$2,590 Positive Results From Phase 2 Lumbar Fusion Trial 21 Oct 2010 10:02AM $2.330 $1.990 fallen by 14.59%
$2,590 Angioblast Stockholders Approve Acquisition By Mesoblast 20 Oct 2010 10:32AM $2.340 $1.990 fallen by 14.96%
$2,590 Mesoblast Targets Broader Cancer Indications 14 Oct 2010 9:28AM $2.550 $1.990 fallen by 21.96%
$2,590 Response to an ASX Price Query 10 Sep 2010 2:44PM $2.280 $1.990 fallen by 12.72%

1051 - 1075 of 1197 results

Page 43 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.